

抑制启动子的三链DNA的结构模建及稳定性研究

Stability and Molecular Modeling of Triplex DNA Inhibiting DNA Binding Protein Binding to the Core Promoter of Hepatitis B Virus

投稿时间: 1999-2-13 最后修改时间: 1999-8-16

稿件编号: 20000316

中文关键词: [三链DNA](#) [反基因策略](#) [同源模建](#) [核心启动子](#) [乙肝病毒 \(HBV\)](#)

英文关键词: [triplex DNA](#) [antigene strategy](#) [homology modeling](#) [core promoter](#) [hepatitis B virus \(HBV\)](#)

基金项目: 国家自然科学基金资助项目 (39770418) .

作者	单位
杨洁	中国科学院昆明动物研究所, 昆明 650223
刘次全	中国科学院昆明动物研究所, 昆明 650223

摘要点击次数: 99

全文下载次数: 9

中文摘要:

在IRIS Indi go2(SGI公司)工作站上,利用Insight II/MSI软件包,以TAT三链DNA为模板,采用同源模建的方法,分别建立起两个含21nt的脱氧寡核苷酸CP1(G3TG2TGT2G5TG2TGT)和CP3(TGTG2TG5T2GTG2TG3)的三维结构.采用分子力学方法进行能量优化,将得到的能量最低结构作为分子的优势构象.研究结果显示,CP1的能量低于CP3的能量,即前者的结构较后者稳定.从而证明了CP1与乙肝病毒(HBV)的核心启动子(Cp)片段之间能稳定地形成三链DNA,并能特异性地抑制DNA结合蛋白与Cp片段的结合.这些结果表明,三链DNA的形成有可能抑制DNA的转录.

英文摘要:

Two three-dimensional structure models of the 21nt oligodeoxyribonucleotides, CP1 (G3TG-2TGT2G5TG2TGT) and CP3 (TGTG2TG5T2-GTG2TG3), were constructed by InsightII (MSI) software in IRIS Indi go2 (SGI) workstation using the crystal structure of TAT triplex formation as the template. The initial structures subsequently were minimized by molecular mechanics. The final structures were believed as the dominant conformation. The results showed that the energy of CP1 is lower than that of CP3, and the former is more stable than the latter. Moreover, the results further proved that the 21nt oligodeoxyribo-nucleotide CP1 stably combines with the core promoter (Cp) fragment of hepatitis B virus (HBV) to form a triplex DNA, and CP1 specifically inhibits a specific cellular factor (DNA binding protein) binding to Cp fragment. These results indicated that specific repression of gene transcription of HBV DNA might be possible by triplex-formation DNA.

[查看全文](#)

[关闭](#)

[下载PDF阅读器](#)

您是第372064位访问者.

主办单位: 中国科学院生物物理研究所和中国生物物理学会 单位地址: 北京市朝阳区大屯路15号
服务热线: 010-64888459 传真: 010-64889892 邮编: 100101 Email: prog@sun5.ibp.ac.cn
本系统由勤云公司设计, 联系电话: 010-62862645, 网址: <http://www.e-tiller.com>

京ICP备05002794号